These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 23599173)

  • 41. MiR-429 is an independent prognostic factor in colorectal cancer and exerts its anti-apoptotic function by targeting SOX2.
    Li J; Du L; Yang Y; Wang C; Liu H; Wang L; Zhang X; Li W; Zheng G; Dong Z
    Cancer Lett; 2013 Feb; 329(1):84-90. PubMed ID: 23111103
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors.
    Dworakowska D; Wlodek E; Leontiou CA; Igreja S; Cakir M; Teng M; Prodromou N; Góth MI; Grozinsky-Glasberg S; Gueorguiev M; Kola B; Korbonits M; Grossman AB
    Endocr Relat Cancer; 2009 Dec; 16(4):1329-38. PubMed ID: 19620247
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Formononetin induces cell cycle arrest of human breast cancer cells via IGF1/PI3K/Akt pathways in vitro and in vivo.
    Chen J; Zeng J; Xin M; Huang W; Chen X
    Horm Metab Res; 2011 Sep; 43(10):681-6. PubMed ID: 21932171
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.
    Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
    Invest Ophthalmol Vis Sci; 2010 Jan; 51(1):421-9. PubMed ID: 19661225
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Overexpressed eIF4E is functionally active in surgical margins of head and neck cancer patients via activation of the Akt/mammalian target of rapamycin pathway.
    Nathan CO; Amirghahari N; Abreo F; Rong X; Caldito G; Jones ML; Zhou H; Smith M; Kimberly D; Glass J
    Clin Cancer Res; 2004 Sep; 10(17):5820-7. PubMed ID: 15355912
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sox2 is involved in paclitaxel resistance of the prostate cancer cell line PC-3 via the PI3K/Akt pathway.
    Li D; Zhao LN; Zheng XL; Lin P; Lin F; Li Y; Zou HF; Cui RJ; Chen H; Yu XG
    Mol Med Rep; 2014 Dec; 10(6):3169-76. PubMed ID: 25310235
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ATP-mediated protein kinase B Akt/mammalian target of rapamycin mTOR/p70 ribosomal S6 protein p70S6 kinase signaling pathway activation promotes improvement of locomotor function after spinal cord injury in rats.
    Hu LY; Sun ZG; Wen YM; Cheng GZ; Wang SL; Zhao HB; Zhang XR
    Neuroscience; 2010 Sep; 169(3):1046-62. PubMed ID: 20678995
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Isorhapontigenin suppresses growth of patient-derived glioblastoma spheres through regulating miR-145/SOX2/cyclin D1 axis.
    Xu Z; Zeng X; Xu J; Xu D; Li J; Jin H; Jiang G; Han X; Huang C
    Neuro Oncol; 2016 Jun; 18(6):830-9. PubMed ID: 26681767
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
    Bago-Horvath Z; Sieghart W; Grusch M; Lackner A; Hayden H; Pirker C; Komina O; Węsierska-Gądek J; Haitel A; Filipits M; Berger W; Schmid K
    Neuroendocrinology; 2012; 96(3):228-37. PubMed ID: 22378048
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Downregulation of miR-144 is associated with colorectal cancer progression via activation of mTOR signaling pathway.
    Iwaya T; Yokobori T; Nishida N; Kogo R; Sudo T; Tanaka F; Shibata K; Sawada G; Takahashi Y; Ishibashi M; Wakabayashi G; Mori M; Mimori K
    Carcinogenesis; 2012 Dec; 33(12):2391-7. PubMed ID: 22983984
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras.
    Wislez M; Spencer ML; Izzo JG; Juroske DM; Balhara K; Cody DD; Price RE; Hittelman WN; Wistuba II; Kurie JM
    Cancer Res; 2005 Apr; 65(8):3226-35. PubMed ID: 15833854
    [TBL] [Abstract][Full Text] [Related]  

  • 52. RNAi-mediated silencing of Anxa2 inhibits breast cancer cell proliferation by downregulating cyclin D1 in STAT3-dependent pathway.
    Zhang F; Wang Z; Yuan J; Wei X; Tian R; Niu R
    Breast Cancer Res Treat; 2015 Sep; 153(2):263-75. PubMed ID: 26253946
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1.
    Zang C; Eucker J; Liu H; Müller A; Possinger K; Scholz CW
    Cancer Lett; 2013 Oct; 339(2):288-97. PubMed ID: 23200668
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Overexpression of BIRC6 Is a Predictor of Prognosis for Colorectal Cancer.
    Hu T; Weng S; Tang W; Xue R; Chen S; Cai G; Cai Y; Shen X; Zhang S; Dong L
    PLoS One; 2015; 10(5):e0125281. PubMed ID: 25933218
    [TBL] [Abstract][Full Text] [Related]  

  • 55. LncRNA SNHG6 inhibits cell proliferation and metastasis by targeting ETS1 via the PI3K/AKT/mTOR pathway in colorectal cancer.
    Meng S; Jian Z; Yan X; Li J; Zhang R
    Mol Med Rep; 2019 Sep; 20(3):2541-2548. PubMed ID: 31322251
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of c2orf68 and PI3K/Akt/mTOR pathway in human colorectal cancer.
    Wen X; Zhu J; Dong L; Chen Y
    Med Oncol; 2014 Aug; 31(8):92. PubMed ID: 25023051
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Polycystin-1 and polycystin-2 are involved in the acquisition of aggressive phenotypes in colorectal cancer.
    Gargalionis AN; Korkolopoulou P; Farmaki E; Piperi C; Dalagiorgou G; Adamopoulos C; Levidou G; Saetta A; Fragkou P; Tsioli P; Kiaris H; Zizi-Serbetzoglou A; Karavokyros I; Papavassiliou KA; Tsavaris N; Patsouris E; Basdra EK; Papavassiliou AG
    Int J Cancer; 2015 Apr; 136(7):1515-27. PubMed ID: 25123959
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Overexpression of SOX2 is involved in paclitaxel resistance of ovarian cancer via the PI3K/Akt pathway.
    Li Y; Chen K; Li L; Li R; Zhang J; Ren W
    Tumour Biol; 2015 Dec; 36(12):9823-8. PubMed ID: 26159849
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Silencing of FOXO6 inhibits the proliferation, invasion, and glycolysis in colorectal cancer cells.
    Li Q; Tang H; Hu F; Qin C
    J Cell Biochem; 2019 Mar; 120(3):3853-3860. PubMed ID: 30321450
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Acemannan accelerates cell proliferation and skin wound healing through AKT/mTOR signaling pathway.
    Xing W; Guo W; Zou CH; Fu TT; Li XY; Zhu M; Qi JH; Song J; Dong CH; Li Z; Xiao Y; Yuan PS; Huang H; Xu X
    J Dermatol Sci; 2015 Aug; 79(2):101-9. PubMed ID: 26049685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.